greeksoup/ stock research

BWX Technologies, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 3 August 2026: press release. Guidance figures: 4 raised. The quarter’s numbers.

Key takeaways

  • Revenue rose 18% on Commercial growth: Revenue was $901.6 million against $764.0 million a year earlier. Commercial Operations revenue rose 72% to $302.5 million, and Government Operations rose 2% to $601.3 million. Source
  • Adjusted EBITDA up 7%: Adjusted EBITDA was $155.5 million against $145.9 million. Commercial Operations adjusted EBITDA rose 123% to $36.1 million, while Government Operations fell 5% to $126.5 million. Source
  • 2026 guidance raised on all measures: The company raised 2026 guidance for revenue, adjusted EBITDA, non-GAAP EPS and free cash flow. The new guidance includes the PCG acquisition, which the prior guidance did not include. Source
  • Commercial operating income up 254%: Commercial Operations operating income was $24.3 million against $6.9 million. Management attributed the increase to higher revenue and solid operational performance, partly offset by SG&A investment to support growth. Source
  • Total backlog reached $8.4 billion: Total backlog was $8,398.1 million at June 30, 2026, against $6,015.2 million a year earlier and $8,650.8 million at March 31, 2026. Source
  • Free cash flow down 9%: Free cash flow was $115.0 million against $126.3 million. Operating cash flow was $156.4 million, down 2%, with management citing timing of income tax payments. Source
  • Medical business sale announced: The company announced the sale of its medical business. Management said the sale lets it focus resources on core nuclear national defense and commercial nuclear power markets. Source
  • PCG acquisition closed July 1: The company closed the PCG acquisition on July 1, 2026, which it described as establishing a U.S. footprint for commercial nuclear component manufacturing. The deal was announced in the first quarter. Source

“Demand for new nuclear solutions is remarkably deep and broad”

Rex. D. Geveden, president and chief executive officer

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceYear ending December 31, 2026~$3,800Raised from >$3,750
Adjusted EBITDA SourceYear ending December 31, 2026$662 million-$672 millionRaised from $650 - $665 million
Non-GAAP EPS SourceYear ending December 31, 2026$4.70-$4.80Raised from $4.60 - $4.75
Free cash flow SourceYear ending December 31, 2026$345 million-$360 millionRaised from $315 - $330 million

What changed from last quarter

  • Guidance raised: 2026 guidance was raised for revenue, adjusted EBITDA, non-GAAP EPS and free cash flow. Source
  • New: The company announced the sale of its medical business. Source
  • New: The Precision Components Group acquisition, announced in the first quarter, closed on July 1, 2026. Source

Results and growth drivers

  • Revenue rose 18% on Commercial growth: Revenue was $901.6 million against $764.0 million a year earlier. Commercial Operations revenue rose 72% to $302.5 million, and Government Operations rose 2% to $601.3 million. Source
  • Operating income up 11%: GAAP operating income was $114.1 million against $102.4 million. Non-GAAP operating income was $126.6 million against $121.1 million, a 5% rise. Source
  • Diluted EPS rose on operating income: GAAP diluted EPS was $0.97, up from $0.85, and non-GAAP EPS was $1.07, up from $1.02. GAAP net income was $89.1 million against $78.5 million. Source
  • Adjusted EBITDA up 7%: Adjusted EBITDA was $155.5 million against $145.9 million. Commercial Operations adjusted EBITDA rose 123% to $36.1 million, while Government Operations fell 5% to $126.5 million. Source
  • Six-month revenue rose to $1,761.8 million: Revenue for the six months ended June 30, 2026 was $1,761.8 million against $1,446.3 million for the same period of 2025. Source
  • 2026 guidance raised on all measures: The company raised 2026 guidance for revenue, adjusted EBITDA, non-GAAP EPS and free cash flow. The new guidance includes the PCG acquisition, which the prior guidance did not include. Source

Segment results

  • Government revenue up 2%, profit down: Government Operations revenue was $601.3 million. Operating income fell 3% to $105.7 million and adjusted EBITDA fell 5% to $126.5 million. The decrease was attributed to higher contract adjustments in the prior-year quarter and less favorable mix. Source
  • Commercial operating income up 254%: Commercial Operations operating income was $24.3 million against $6.9 million. Management attributed the increase to higher revenue and solid operational performance, partly offset by SG&A investment to support growth. Source
  • Corporate expense rose: Unallocated corporate expense was $15.9 million against $13.9 million. Corporate adjusted EBITDA was a $7.1 million charge against a $3.3 million charge. Source

“contribution from the recently completed PCG acquisition, and confidence in our execution over the remainder of the year, we are raising our 2026 financial guidance”

Rex. D. Geveden, president and chief executive officer

Products and customers

  • Commercial growth across product lines: Commercial revenue growth came from commercial nuclear components, field services, fuel handling, medical and the Kinectrics contribution. Fuel revenue was slightly lower. Source
  • Naval propulsion and special materials grew: Government revenue growth came from naval propulsion and special materials, partly offset by lower advanced nuclear volumes. Source

Costs and other income

  • Cost of operations rose with revenue: Cost of operations was $699.3 million against $572.6 million a year earlier, while revenue rose 18%. Source
  • SG&A rose to $108.4 million: SG&A was $108.4 million against $102.9 million. The company described SG&A spending as investment to support growth. Source
  • Tax rate and other income weighed on EPS: Effective tax rate was 21.6% against 19.7% a year earlier. Management said lower other income and the higher tax rate partly offset gains from operating income and lower interest. Source
  • Interest expense and other income fell: Interest expense fell to $5.3 million from $11.7 million. Other income, net, was $0.3 million against $6.5 million. Source
  • Equity income from investees rose: Equity in income of investees was $24.4 million against $18.5 million. Management cited higher technical services equity income within Government Operations. Source

“the announced sale of our medical business enables us to increase focus and resources in these core business lines”

Rex. D. Geveden, president and chief executive officer

Demand and order book

  • Total backlog reached $8.4 billion: Total backlog was $8,398.1 million at June 30, 2026, against $6,015.2 million a year earlier and $8,650.8 million at March 31, 2026. Source
  • Segment backlog fell from first quarter: Government backlog was $6,797.6 million, down from $6,931.1 million, and Commercial backlog was $1,600.5 million, down from $1,719.7 million, at March 31, 2026. Source
  • Quarterly bookings fell year over year: Bookings in the quarter were $648.9 million against $1,640.5 million a year earlier. Government bookings were $467.6 million, against $1,412.3 million. Source
  • Six-month bookings rose year over year: Six-month bookings were $2,899.2 million against $2,360.3 million a year earlier, with Government bookings at $2,435.3 million. Source

Cash, capital and dividend

  • Free cash flow down 9%: Free cash flow was $115.0 million against $126.3 million. Operating cash flow was $156.4 million, down 2%, with management citing timing of income tax payments. Source
  • Capital spending up 27%: Capital expenditures were $41.4 million against $32.7 million, up 27%. The company attributed the rise to timing of growth projects, mainly in Commercial Operations. Source
  • Dividend of $0.27 paid in quarter: BWXT paid $24.7 million in dividends, or $0.27 per common share, in the second quarter, against $23.1 million a year earlier. Source
  • Six-month operating cash flow and capex: Six-month operating cash flow was $249.0 million against $209.7 million, and capital expenditures were $83.9 million against $66.1 million. Source
  • No share repurchases in six months: The six-month cash flow statement shows no common stock repurchases in 2026, against $30.0 million in 2025. Dividends paid to common shareholders were $50.4 million. Source
  • Cash and debt at June 30: Cash and cash equivalents were $608.2 million at June 30, 2026, against $499.8 million at December 31, 2025. Long-term debt was $2,019.9 million. Source

Strategy, portfolio and footprint

  • Medical business sale announced: The company announced the sale of its medical business. Management said the sale lets it focus resources on core nuclear national defense and commercial nuclear power markets. Source
  • PCG acquisition closed July 1: The company closed the PCG acquisition on July 1, 2026, which it described as establishing a U.S. footprint for commercial nuclear component manufacturing. The deal was announced in the first quarter. Source
  • Manufacturing capacity investment continues: Management said ongoing investments drive capacity and modernization across the manufacturing footprint, alongside the U.S. commercial manufacturing expansion. Source
  • Workforce and facilities increased: The company describes more than 11,000 employees and 19 manufacturing facilities, against approximately 10,000 employees and 17 facilities in the first-quarter release. Source

Coming up, as management said on 3 August 2026

  • Dividend payable September 4: The board declared a $0.27 quarterly dividend on July 31, 2026, payable September 4 to holders of record on August 18. Source

Figures management reported

FigureReported
Total backlog Source$8,398.1 million
Government backlog Source$6,797.6 million
Commercial backlog Source$1,600.5 million
Quarterly bookings Source$648.9 million
Government bookings Source$467.6 million
Manufacturing facilities Source19

Earlier plans management reported on

  • Ahead: Management said second quarter 2026 results were ahead of its expectations. Source
  • Not stated: The first-quarter release said capital would be deployed organically and inorganically to add industrial scale.
  • Not stated: Management said the strategy is already in action through the commercial manufacturing expansion in the U.S. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.